Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Abuse-deterrent Immediate Release Oral Ketamine Capsules for Treatment Resistant Bipolar Depression: A Phase 2A, Randomised, Double-blind, Placebo-controlled Study

NCT07644767 is registered in ClinicalTrials.gov with Neurocentrx Pharma Pty Ltd as lead sponsor.

NCT NCT07644767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07644767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Abuse-deterrent Immediate Release Oral Ketamine Capsules for Treatment Resistant Bipolar Depression: A Phase 2A, Randomised, Double-blind, Placebo-controlled Study
Lead sponsor
Neurocentrx Pharma Pty Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
June 30, 2028
Enrollment
160 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant bipolar depression